HoldsUp

Eran Elinav

Weizmann Institute of Science and German Cancer Research Center

Eran Elinav, MD, PhD, is a professor of immunology and principal investigator at the Weizmann Institute of Science and the German Cancer Research Center, where he co-directs the Personalized Nutrition Project. His research focuses on host-microbiome interactions and how gut bacteria impact human health and disease. His published work investigates topics including personalized nutrition, dietary assessment, mucosal immunity, metabolic disorders, and cancer-microbiome interactions.

53 claims checked on air: 2 context 6 overstated 42 supported 3 unverified

What they said on air

5 citing their own research

0:02:01supportedmoderateDr. Eran Elinav on Microbiome Insights into Personalized Res

The timing of food intake has an independent effect on the composition and metabolic/circadian function of gut microbes across a 24-hour cycle.

"actually the timing of diet has an independent and very peculiar effect on the composition and on the function of our gut microbes. And through these time-dependent interactions, our gut microbiome can independently impact our metabolic health or our propensity to develop diseases such as obesity and type 2 diabetes." (said at 0:02:01)

Studies in both animal models and humans demonstrate that feeding timing directly drives diurnal fluctuations in gut microbial composition and functional pathways across a 24-hour cycle. Disruptions to these rhythmic feeding patterns alter microbiome diurnal oscillations and contribute to metabolic disturbances such as glucose intolerance and obesity, effects that were shown to be transferable via fecal microbiota transplantation.

0:05:34supportedlowDr. Eran Elinav on Microbiome Insights into Personalized Res

Disrupting circadian microbial rhythmicity via altered feeding patterns or jet lag promotes host susceptibility to obesity and type 2 diabetes.

"And once we disrupt the circadian microbial activity, for example by changing the patterns of our diet or by subjecting mice to jet lag behavior, the microbes go crazy and stop behaving in this orderly manner throughout the course of a day. And this directly reflects on how the host behaves in its normal circadian behavior, and we found that once we disrupt the microbes, the host is now susceptible to develop obesity and type 2 diabetes" (said at 0:05:34)

The speaker's statement accurately summarizes published experimental findings demonstrating that disrupting the diurnal oscillations of the gut microbiome—via altered feeding schedules, host molecular clock ablation, or simulated jet lag—results in dysbiosis and loss of microbial rhythmicity. In mice and human fecal transfer models, this jet-lag-induced microbial disruption led to glucose intolerance and obesity. Because these causal findings rely primarily on animal models and small-scale human fecal transplantation experiments into germ-free mice, the certainty of the evidence for broad human disease etiology is low.

0:06:10supportedmoderateDr. Eran Elinav on Microbiome Insights into Personalized Res

Shift workers who experience chronic sleep-wake disturbances are at a substantially higher risk of developing obesity and type 2 diabetes.

"such as shift workers that are at a substantial risk of developing obesity and type 2 diabetes." (said at 0:06:10)

Extensive meta-analyses and umbrella reviews of prospective cohort studies consistently demonstrate that shift workers—particularly night and rotating shift workers experiencing circadian and sleep disruption—have a significantly elevated risk of developing both obesity and type 2 diabetes. Meta-analyses report an approximately 30% to 40% increased relative risk of incident type 2 diabetes among shift workers compared to daytime workers, as well as significantly higher odds of overweight and obesity (odds ratio ~1.43 for fixed night shifts).

0:07:35supportedvery lowDr. Eran Elinav on Microbiome Insights into Personalized Res

Time-restricted feeding can completely restore normal microbiome circadian rhythmicity and downstream host metabolic and immune function in jet-lagged or clock-deficient mice.

"However, if we take all of these disrupted conditions and now we time-restrict the feeding of these mice to imitate the normal eating behavior in non-disrupted mice, then we can completely restore the microbiome circadian activity and its effect on the metabolic and immune function of the host." (said at 0:07:35)

Preclinical animal research from Thaiss and colleagues demonstrated that disruption of host circadian rhythms (through molecular clock ablation such as Per1/2 deficiency or simulated jet lag) disrupts diurnal feeding patterns, leading to loss of microbiome diurnal oscillations, dysbiosis, and impaired host metabolic homeostasis. Time-restricted feeding during the normal nocturnal active phase restored microbial diurnal compositional fluctuations, biogeographical localization, metabolome rhythms, and downstream host metabolic and transcriptional oscillations in these mouse models. Because the finding is based primarily on preclinical rodent experiments, the certainty of evidence is very low.

0:14:00unverifiedvery lowDr. Eran Elinav on Microbiome Insights into Personalized Res

In industrialized nations, individuals are routinely exposed to no more than 40 or 50 dietary components in their standard lifestyle.

"We discovered that even in industrialized nations, uh, people are usually exposed to no more than 40 or 50 components of of dietary dietary composition, um, in a routine lifestyle." (said at 0:14:00)

No published record matching the claim that individuals in industrialized nations are routinely exposed to no more than 40 or 50 components of dietary composition in a routine lifestyle was located; this does not prove the claim false.

0:14:30unverifiedvery lowDr. Eran Elinav on Microbiome Insights into Personalized Res

From a bird's-eye view, human microbiome composition remains largely stable from approximately age three until old age in healthy adults without disease or lifestyle perturbations.

"if you just, uh, you know, look into the composition and the function of the microbiome from from this resolution, you would find that it changes, uh, um, very in a very minor manner between the age of three until we get, uh, to an old age or if we develop disease or change our lifestyle." (said at 0:14:30)

No published record matching the claim that human gut microbiome composition and function remain largely stable from approximately age three until old age in the absence of disease or lifestyle perturbations was located; this does not prove the claim false.

0:15:10supportedmoderateDr. Eran Elinav on Microbiome Insights into Personalized Res

In African populations, seasonal changes between rainy and dry seasons cause consistent, reproducible shifts in the gut microbiome due to different crop availability.

"For example, there are studies in Africa looking into rainy or dry seasons, which are characterized by different exposures to different crops and different foods, and and you can see that this is a very consistent and very reproducible change that that is based on the changes in the in in the, um, in these seasons and and what they represent." (said at 0:15:10)

Longitudinal studies tracking traditional African populations across seasonal cycles, most notably the Hadza of Tanzania, demonstrate cyclic and reproducible reconfigurations of the gut microbiota. Distinct taxonomic groups disappear and reappear in correspondence with the dietary shifts between wet and dry seasons (such as seasonal availability of honey, berries, tubers, and game).

0:16:37supportedmoderateDr. Eran Elinav on Microbiome Insights into Personalized Res

Abruptly changing a diet from vegetarian to carnivore reproducibly shifts the average population gut microbiome composition to accommodate the new macronutrient profile.

"if you abruptly change the composition of the diet, um, from one type to another, for example, from a veggie to a carnivore diet, uh, um, you very reproducibly change—in an average, in a population average, you very reproducibly change the composition of the microbe into one which accommodates better the new diet." (said at 0:16:37)

A landmark controlled dietary intervention study by David et al. (2014) demonstrated that abruptly transitioning healthy human volunteers between entirely plant-based and entirely animal-based diets rapidly and reproducibly altered gut microbial community structure and gene expression. The animal-based diet increased bile-tolerant organisms (such as Alistipes and Bilophila) and shifted metabolic activity toward amino acid fermentation, while the plant-based diet enriched microbes that ferment dietary plant polysaccharides, mirroring functional differences between carnivorous and herbivorous mammals.

0:17:25unverifiedvery lowDr. Eran Elinav on Microbiome Insights into Personalized Res

In a 2015 trial, healthy individuals fed only white rice for a week followed by only steak for a week showed consistent and reproducible directions of change in their gut microbiota.

"in 2015, we've conducted our own, uh, kind of mini, uh, trial in which we took a group of, uh, healthy human individuals and we've asked them politely to eat only white rice for a week, then only, you know, a steak for another week, while we extensively measured them, uh, for their microbiome, and we found indeed that the microbiome changes in a very reproducible manner." (said at 0:17:25)

No published record matching a 2015 trial in which healthy human participants consumed exclusively white rice for one week followed exclusively by steak for one week was located; this does not prove the claim false. The primary 2015 personalized nutrition study from this research group evaluated personalized multi-component dietary interventions rather than mono-diet crossover regimens.

0:18:45overstatedlowDr. Eran Elinav on Microbiome Insights into Personalized Res

Indigenous hunter-gatherer populations can have a gut microbiome diversity that is tenfold higher than that of individuals living in modern industrialized societies.

"if you look at indigenous populations of humans, uh, hunter-gatherers and so on and so forth, you would find, um, in some studies that the diversity of the microbiome can be tenfold higher than the average diversity that we, um, can see and measure, um, in in the same human beings when they live in modern, quote-unquote, societies or industrialized societies." (said at 0:18:45)

Observational metagenomic studies comparing traditional hunter-gatherer and isolated indigenous populations (such as the Hadza of Tanzania and uncontacted Yanomami Amerindians) to urban industrialized cohorts show that indigenous populations harbor significantly higher microbial richness and alpha diversity. However, describing this difference as 'tenfold higher' (1000% higher) is a substantial overstatement. Comparative studies demonstrate modest increases (e.g., approximately 30–50% higher diversity metrics in isolated groups compared to Western urban controls), far below a 10-fold difference.

0:23:10supportedmoderateDr. Eran Elinav on Microbiome Insights into Personalized Res

Early life exposure to antibiotics in mice and humans increases the risk of developing asthma and obesity later in life.

"And especially in mice, but also to some extent in humans, um, it was shown that, uh, early life exposure to antibiotics, for example, uh, could save lives in many cases, but the price that we may pay is an increased risk for these diseases such as asthma—these are elegant studies that were performed by my friend and colleague Brett Finlay—and to obesity in later life" (said at 0:23:10)

Experimental animal research and observational human studies support the claim. In murine models, early-life exposure to antibiotics perturbing the gut microbiome increases susceptibility to allergic asthma (Russell et al., 2012). In human prospective cohorts and systematic reviews, early postnatal antibiotic exposure is associated with increased risk and incidence of childhood asthma (Patrick et al., 2020) as well as childhood overweight and obesity (Rasmussen et al., 2018; Asgari et al., 2023), particularly with repeated courses or treatment in the first months of life.

0:25:28supportedmoderateDr. Eran Elinav on Microbiome Insights into Personalized Res

Autoimmune and autoinflammatory diseases are significantly less prevalent in countries with higher early-life exposure to environmental infections compared to cleaner, industrialized nations.

"supported, for example, by epidemiological um evidence of of some of the autoimmune or autoinflammatory diseases being much less prevalent in kind of, you know, quote-unquote uh dirtier countries or countries in which um um the prevalence of exposure at early life to environmental infection is higher as compared to um cleaner, quote-unquote, countries which suffer from an uh from a marked increase in in these autoimmune or other inflammatory diseases." (said at 0:25:28)

Extensive epidemiological, ecological, and migration data support the observation that autoimmune and chronic inflammatory diseases (such as type 1 diabetes, multiple sclerosis, and inflammatory bowel disease) have a markedly lower prevalence in developing nations with high early-life microbial and infectious exposure compared to highly sanitized, industrialized nations. Furthermore, migration studies demonstrate that individuals moving from countries with low disease incidence and high infectious burdens to industrialized countries adopt the higher risk of autoimmune and allergic disorders within the first generation. While observational and ecological data do not definitively prove causality in humans, the epidemiological inverse correlation is well-documented and corroborated by experimental animal models.

0:25:28supportedmoderateDr. Eran Elinav on Microbiome Insights into Personalized Res

Early-life microbiome disruption or depletion increases susceptibility to developing inflammatory bowel disease (IBD) later in life.

"They're very elegant studies by my colleague um Martin Blaser from from NYU showing um in mice and I think also in humans that uh um that that this overly uh uh uh um these distinct uh um depletion or changes on the development of the microbiome could impact on the susceptibility to develop diseases such as inflammatory bowel disease in later life." (said at 0:25:28)

Experimental animal research and human epidemiological data support the claim that early-life microbiome disruption increases susceptibility to inflammatory bowel disease (IBD) later in life. Studies from Martin Blaser's group demonstrated that a single early-life course of antibiotics in mice exacerbated subsequent dextran sodium sulfate-induced colitis and that fecal transfer of the perturbed microbiota alone conferred increased disease severity. In humans, a systematic review and meta-analysis of observational studies found childhood antibiotic exposure was associated with an increased risk of developing IBD (RR 1.42, 95% CI 1.23–1.66), including Crohn's disease (RR 1.59) and ulcerative colitis (RR 1.23).

0:28:00supportedmoderateDr. Eran Elinav on Microbiome Insights into Personalized Res

Human infants are born sterile and acquire their gut microbiome postnatally from immediate surroundings and parents.

"First of all, um every child is born um sterile, to the best of our knowledge, and acquires his or her microbiome during the neonatal period from his or her immediate surrounding, which mainly consists of their parents who are very close to them." (said at 0:28:00)

The speaker's statement reflects the prevailing scientific consensus regarding the 'sterile womb hypothesis' and initial infant microbiome colonization. Although several 16S rRNA gene sequencing studies in the 2010s suggested bacterial presence in the placenta, amniotic fluid, and meconium, subsequent comprehensive re-analyses and well-controlled low-biomass metagenomic studies demonstrated that these signals were largely artifacts of reagent contamination, laboratory background DNA, or delivery exposure. Current evidence indicates that healthy human fetuses develop in a sterile environment and undergo initial, massive microbial colonization during and after birth from maternal and environmental exposures.

0:29:15supportedmoderateDr. Eran Elinav on Microbiome Insights into Personalized Res

A study of 500 individuals showed that only 1.9% of gut microbiome variability is explained by human genetics, while nearly 99% is explained by environmental factors.

"What we found was that most of the effect shaping our microbiome comes from the environment. Only 1.9% of the variability in the human microbiome could be explained by differences in the human genes, while close to 99% of the variability in the human microbiome was explainable by factors coming from people's environment." (said at 0:29:15)

A landmark 2018 study by Rothschild et al. in Nature examined genotype and gut microbiome data from over 1,000 healthy individuals to quantify the relative contributions of host genetics versus environmental factors. The authors found that host genetics plays a minimal role, with an average SNP-based heritability (h2_SNP) of approximately 1.9% across taxa, while environmental factors (such as shared household, diet, lifestyle, and medications) dominate inter-individual microbiome variation.

0:29:55supportedmoderateDr. Eran Elinav on Microbiome Insights into Personalized Res

Human height is determined almost entirely by host genetics with no microbiome contribution, whereas metabolic traits like weight, waist-to-hip ratio, and cholesterol are substantially influenced by both host genetics and the gut microbiome.

"So, for example, if you look at human height, it is not affected by the microbes whatsoever. So almost all of the explanation for differences in human height came from the human genes and not from the microbes. However, when we looked at a number of metabolic parameters such as weight, uh waist-to-hip ratio, cholesterol levels, and many other metabolic features, we found that the microbes, the microbiome, and the human genes had independent and very substantial effects on these traits." (said at 0:29:55)

A landmark 2018 study (Rothschild et al., Nature) analyzing genotype and microbiome data from 1,046 healthy individuals evaluated the relative contributions of host genetics (heritability) and gut microbiome composition (microbiability) across multiple human phenotypes. They demonstrated that while human height has high genetic heritability with virtually zero microbiome contribution, metabolic and anthropometric traits—including body mass index, waist-to-hip ratio, fasting glucose, and cholesterol measures—exhibited substantial and significant microbiability, with microbiome data significantly improving trait prediction beyond host genetics alone.

0:32:37needs contextmoderateDr. Eran Elinav on Microbiome Insights into Personalized Res

In the Personalized Nutrition Project and subsequent interventional trials, personalized dietary modifications led to improvements in HDL cholesterol.

"So, for example, in the Personalized Nutrition Project and in interventional trials that were followed as part of this project, we found that modification of the personalized nutritional recommendations could lead to an improvement in HDL cholesterol, the good cholesterol." (said at 0:32:37)

The Personalized Nutrition Project investigated machine-learning algorithms incorporating microbiome, dietary, anthropometric, and clinical blood markers to design personalized diets targeting postprandial glycemic responses. In randomized dietary interventions from the project, personalized diets significantly reduced postprandial glycemic excursions and modified metabolic and microbiome profiles. While cardiometabolic parameters and blood lipids are tracked as broader metabolic consequences of these personalized dietary interventions, the primary focus of the foundational trials was glycemic control.

0:33:00supportedmoderateDr. Eran Elinav on Microbiome Insights into Personalized Res

The PREDICT trial demonstrated that gut microbiome and host data can be used to predict an individual's triglyceride levels.

"Another group from the UK conducted a very ambitious follow-up trial similar to the Personalized Nutrition Project, which we started with, called the PREDICT trial. And in this trial, they could show something very exciting, which is that the microbiome and the host could use to predict a person's triglyceride levels." (said at 0:33:00)

The PREDICT 1 study (Personalised REsponses to DIetary Composition Trial, n = 1,002 healthy adults and twins in the UK, validated in a 100-person US cohort) demonstrated that person-specific factors—particularly the gut microbiome—substantially influenced postprandial blood triglyceride responses. Using machine-learning models incorporating gut microbiome, host characteristics, and meal composition, the investigators successfully predicted individual postprandial triglyceride responses (Pearson r = 0.47).

0:36:55supportedvery lowDr. Eran Elinav on Microbiome Insights into Personalized Res

Mice exposed to saccharin developed microbiome-driven disturbances in glycemic response that were transferable to germ-free mice via fecal microbiome transfer.

"And what we found to our very big surprise was that um mice featured a counterintuitive disturbance in their glycemic responses when they were exposed to saccharin, and this was driven by their microbiome. So, for example, when you exposed mice to to um saccharin at different doses and took the microbiome after this exposure and transferred it into germ-free mice that never saw saccharin, they developed the same disturbances um in blood sugar control as those of the donor mice." (said at 0:36:55)

A landmark 2014 animal and human study published in Nature demonstrated that mice consuming non-caloric artificial sweeteners (specifically saccharin) developed glucose intolerance driven by alterations in the gut microbiota. Transferring the fecal microbiota from saccharin-consuming mice into naive germ-free mice transferred this impaired glycemic response. Because this specific finding is based on animal experimental data, the GRADE certainty is rated as very low.

0:39:52supportedmoderatetheir own paperDr. Eran Elinav on Microbiome Insights into Personalized Res

A preliminary small-scale study found that personalized glycemic responses to saccharin in humans occurred and were transferable to germ-free mice via microbiome transfer.

"So with the artificial sweeteners, as part of the original study, we we published a very preliminary small-scale study suggesting that personalized responses um to uh saccharin in humans do occur, and it could be even transferred upon microbiome transfers from human into humans into germ-free mice." (said at 0:39:52)

The speaker accurately describes published findings from their research group (Suez et al., 2014 in Nature, followed by a randomized controlled trial in 2022 in Cell). In the original preliminary human study, healthy volunteers consuming saccharin showed personalized glycemic responses (some developing impaired glucose tolerance while others did not). Fecal microbiota transplantation from human responders into germ-free (gnotobiotic) mice transferred the impaired glycemic phenotype, whereas transfer from non-responders did not.

0:42:27overstatedhightheir own paperDr. Eran Elinav on Microbiome Insights into Personalized Res

Over 100,000 individuals have been tested on thousands of food components and food additives through the Personalized Nutrition pipeline.

"and we've tested thousands of them in in over 100,000 people that underwent our personalized nutrition uh pipeline or project—we found that people distinctly react to foods or food components or food additives, even if they're exposed to the same exact amounts of the same exact component." (said at 0:42:27)

Published peer-reviewed literature from the Personalized Nutrition Project supports the core premise that individuals demonstrate distinct, personalized glycemic and metabolic responses when exposed to identical foods or food additives (PMID: 26590418, PMID: 35987213). However, claiming that over 100,000 individuals were tested across thousands of food components within this research pipeline overstates the cohort sizes published in peer-reviewed studies. The primary study establishing the Personalized Nutrition Project evaluated continuously monitored glycemic responses to 46,898 meals in an 800-person cohort with an independent 100-person validation cohort (PMID: 26590418). Specific clinical trials investigating food additives (such as non-nutritive sweeteners) were conducted in cohorts of 120 participants (PMID: 35987213).

0:44:59overstatedmoderateDr. Eran Elinav on Microbiome Insights into Personalized Res

Up to 80% of obese individuals who lose weight regain all lost weight within 12 months.

"And this phenomenon, which is medically called recurrent obesity, but is more widely known as yo-yo obesity, characterizes up to 80% of all obese individuals worldwide... but then within 12 months of successfully dieting, 80% of people go on to redevelop obesity or regain all the weight that they've lost, and even regain a little bit more than they originally had." (said at 0:44:59)

The claim overstates the degree and rapidity of weight regain after dieting. The widely cited ~80% figure originates from epidemiological and registry definitions showing that approximately 20% of overweight individuals successfully maintain a weight loss of at least 10% of initial body weight for at least one year (meaning ~80% fail to maintain that specific long-term target). However, failing to maintain a 10% weight reduction is not equivalent to regaining 100% (or more) of lost weight within 12 months; structured weight-loss trials show that individuals typically retain a significant portion of weight loss at 12 months, with full regain occurring more gradually over 3 to 5 years.

0:46:20supportedvery lowDr. Eran Elinav on Microbiome Insights into Personalized Res

In mouse models of recurrent obesity, mice subjected to cycles of obesogenic and low-fat diets regain progressively more weight across cycles compared to never-obese mice.

"And what we could see was exactly the same phenomenon that is observed in humans: from cycle to cycle, mice seemed to regain more and more weight, even when they started from the exact same weight as never-obese mice and were exposed to the same exact diet." (said at 0:46:20)

In published mouse models of recurrent obesity (yo-yo dieting), mice subjected to cycling between high-fat and normal chow diets exhibit accelerated and excessive weight regain upon re-exposure to obesogenic feed compared to primary weight gain in never-obese controls starting at the same baseline weight. Because this evidence is derived entirely from animal models, the GRADE certainty is very low.

0:47:05supportedvery lowDr. Eran Elinav on Microbiome Insights into Personalized Res

Following successful dieting in mice, hormonal, endocrine, and metabolic parameters normalize, but the gut microbiome persistently retains an altered configuration similar to that during obesity.

"And it seems that everything seemed to normalize after a successful diet—all the hormonal and the endocrine and the metabolic features that we could measure totally normalized after a successful diet, other than the gut microbiome. When we measured the gut microbiome, it seemed to be persistently disturbed, as though the mice were never dieted. It had a configuration which was very similar to the one that we observed during obesity." (said at 0:47:05)

A 2016 mouse study published in Nature demonstrated that after diet-induced weight loss in obese mice, physiological and metabolic markers normalized, but the gut microbiome retained an altered composition ("microbiome memory") resembling the obese state for months post-dieting. This persistent dysbiosis promoted accelerated weight regain upon re-exposure to a high-fat diet. Because this evidence is derived exclusively from preclinical rodent models, the overall GRADE certainty is very low.

0:47:40supportedvery lowDr. Eran Elinav on Microbiome Insights into Personalized Res

Transferring the post-dieting microbiome from previously obese mice into germ-free mice induces obesity and type 2 diabetes upon re-exposure to an obesogenic diet.

"And when we took this um microbiome that never normalized after a successful diet and transferred it into germ-free mice, these mice developed obesity and type 2 diabetes, meaning that this post-dieting microbiome stored a metabolic memory of past obesity that predisposed the mice to an exaggerated weight regain the next time they were exposed to an obesogenic diet." (said at 0:47:40)

A 2016 study led by the speaker's research group (Thaiss et al., Nature) demonstrated that mice subjected to cycles of obesity and successful dieting retained an altered gut microbiome signature. When this post-dieting microbiota was transferred into germ-free mice, recipient mice exhibited accelerated weight regain and metabolic perturbations upon re-exposure to a high-fat diet compared to controls receiving microbiota from naive lean mice. Because this finding is based entirely on preclinical mouse models, the GRADE certainty is very low regarding translation to humans.

0:48:15supportedvery lowDr. Eran Elinav on Microbiome Insights into Personalized Res

The post-dieting gut microbiome drives exaggerated weight regain by expanding bacteria that degrade dietary isoflavonoids, preventing them from signaling adipose cells to release heat and store less fat.

"And when we probed even deeper into this memory microbiome, we found that it induced this trait of exaggerated weight regain by altering its ability to degrade dietary compounds which are called isoflavonoids. Normally, we found that isoflavonoids from diet are degraded by the microbiome to compounds which swim into adipose cells and signaling and signal to them to um to release more heat and store less fat when we are exposed to an obesogenic diet. But when these compounds were missing after a successful diet, the adipose cells, the fat cells, were no longer given the signal to release heat and not to store fat, and now they were storing more fat and making the mice more obese as compared to non-yo-yo obesity mice." (said at 0:48:15)

The speaker accurately describes the mechanism identified in their laboratory's mouse model of recurrent post-dieting obesity (yo-yo dieting). In this study (Thaiss et al., 2016), weight cycling in mice left a persistent intestinal microbiome alteration that accelerated the degradation and depletion of dietary flavonoids (such as apigenin and naringenin). This loss of flavonoid signaling led to reduced brown adipose tissue thermogenesis (energy expenditure), driving faster weight regain upon re-exposure to a high-fat diet. Because this mechanism was demonstrated exclusively in preclinical mouse experiments, GRADE certainty for human application is very low.

0:51:15supportedvery lowDr. Eran Elinav on Microbiome Insights into Personalized Res

Resupplementing post-dieting mice with missing flavonoid metabolites or resetting their microbiome via fecal microbial transplantation prevents exaggerated weight regain.

"And indeed, at least in mice, what we've found was that if we intervened by resupplementing our mice with these now missing metabolites, we could avoid or treat exaggerated weight regain and the obesity that it induces. A different approach that we've used in mice and seemed to be highly effective is the replacement of this bad memory microbiome with a microbiome that had the ability to generate the right compounds. And by fecal microbial transplantation, at least in mice, we could reset the mice to not develop this yo-yo obesity phenotype." (said at 0:51:15)

In a 2016 mouse study published in Nature, researchers demonstrated that following diet-induced weight loss, an altered gut microbiome signature persisted and drove accelerated weight regain. This post-dieting microbiome led to diminished flavonoid levels (such as apigenin and naringenin) and impaired energy expenditure. Resupplementing mice with these depleted flavonoids (a 'post-biotic' intervention) or transferring a naive/control microbiome via fecal microbiota transplantation mitigated or prevented exaggerated secondary weight regain upon high-fat diet re-exposure. Because the findings are currently limited to preclinical animal models, certainty is very low.

0:56:30supportedmoderateDr. Eran Elinav on Microbiome Insights into Personalized Res

Around 50% of all small molecules (metabolites) found in the peripheral blood of animals and humans originate from or are modulated by the gut microbiome.

"In fact, we and others have measured the small molecule repertoire in peripheral blood of both animals and humans, and it seems that around 50% of all small molecules that are found within our peripheral blood may originate in one way or another or be modulated in one way or another by our gut microbes." (said at 0:56:30)

Metabolomic comparisons between germ-free and conventionally colonized mammalian models demonstrate that the gut microbiota exerts a massive influence on the circulating metabolome. Seminal untargeted metabolomics profiling (Wikoff et al., 2009) demonstrated that hundreds of circulating plasma metabolite features were unique to conventionally colonized animals or altered in level, with subsequent studies confirming that a large fraction (often estimated up to ~30-50% or more of detected small-molecule features) in mammalian blood is derived from, modified by, or dependent upon commensal microbial metabolism (such as indoles, secondary bile acids, phenyl derivatives, and short-chain fatty acids). The speaker's statement accurately summarizes findings from mammalian comparative metabolomics literature.

0:58:22supportedhighDr. Eran Elinav on Microbiome Insights into Personalized Res

The intestinal barrier separating the gut microbiome and intestinal lumen from the internal body consists of a single layer of intestinal epithelial cells.

"and the trillions of microbes that are in the intestinal lumen and are, you know, separated from our sterile self by only a single layer of intestinal epithelial cells." (said at 0:58:22)

The human intestinal epithelium is an established anatomical structure consisting of a simple (single-layer) columnar epithelium. This single layer of intestinal epithelial cells, linked by tight junctions and coated by mucus, forms the primary physical barrier separating luminal contents—including trillions of commensal microorganisms—from the underlying lamina propria, immune compartments, and internal circulation.

1:02:26supportedhighDr. Eran Elinav on Microbiome Insights into Personalized Res

The gut epithelial barrier is composed of cells connected by tightly regulated junctions that can be influenced by food molecules and microbial molecules.

"and it is composed of the lining cells of the gut, the epithelial cells of the gut, which are characterized by very specific connections to one another which are tightly regulated. And these tightly regulated connections between the cells could be influenced by molecules that come from food, they could be influenced by molecules that come from the microbes, and once this regulation is disrupted, then leaky gut occurs." (said at 1:02:26)

The speaker's description accurately reflects established physiological principles regarding the intestinal barrier. The gut mucosal layer is composed of epithelial cells bound together by specialized protein complexes called tight junctions (including claudins, occludins, and zonula occludens). These tight junctions tightly regulate paracellular permeability and are responsive to both microbial signals (such as short-chain fatty acids, indoles, and bile acid derivatives) and dietary components (such as specific lipids, carbohydrates, and phytochemicals). Disruption of these regulated junctional complexes increases epithelial permeability, leading to the condition clinically described as intestinal hyperpermeability or leaky gut.

1:02:58supportedmoderateDr. Eran Elinav on Microbiome Insights into Personalized Res

The generation and preservation of the protective gut mucus layer is regulated by bacterial and environmental factors, including medications, toxins, and food components.

"And it is increasingly shown that the generation and the preservation of this protective mucus is also regulated by a number of bacterial and environmental factors such as medications, toxins, and food components." (said at 1:02:58)

The speaker accurately states that the generation, maintenance, and regulation of the intestinal mucus layer are influenced by gut microbiota and environmental factors, including dietary components, ingested toxins (such as alcohol), and pharmacological agents. Published reviews demonstrate that interactions between the gut microbiota, dietary components, and environmental exposures play a key role in modulating mucin secretion by goblet cells and maintaining intestinal mucosal integrity.

1:04:34supportedhighDr. Eran Elinav on Microbiome Insights into Personalized Res

Gliadin is a major protein in bread that triggers an immune cascade resulting in increased intestinal permeability in genetically susceptible individuals with celiac disease.

"For example, gliadin is the major protein that is a part of bread, what makes our dough sticky and what makes our bread tasty. And in individuals that suffer from a genetic susceptibility to develop immune reactivity to this protein, then a cascade of immune reaction occurs that leads, among many other changes, to a leaky bowel or to a leaky gut, which contributes to a disease state in the celiac patients." (said at 1:04:34)

Extensive pathophysiological and clinical research confirms that gliadin (a major protein component of wheat gluten) triggers an immune-mediated cascade in genetically susceptible individuals (principally carrying HLA-DQ2 or HLA-DQ8 haplotypes), leading to zonulin upregulation, tight junction disassembly, increased intestinal permeability ('leaky gut'), and enteropathy characteristic of celiac disease.

1:08:40supportedmoderateDr. Eran Elinav on Microbiome Insights into Personalized Res

In a study testing 11 over-the-counter probiotic strains in humans and mice, the indigenous microbiome prevented the probiotics from colonizing the gut in approximately half of human participants.

"when we studied probiotics—we studied 11 different types of commonly prescribed over-the-counter probiotics, and we studied them both in mice and in humans in probably the most invasive microbiome study performed to date—we found that in around half the people that we've tested, when they take these probiotic bacteria and supplement them into their diet, the probiotics are met with a very hostile indigenous microbiome which does not let them colonize our gut even temporarily." (said at 1:08:40)

The speaker accurately describes their 2018 study published in Cell (Zmora et al., 2018). In that trial, researchers administered an 11-strain commercial probiotic preparation to mice and human volunteers, using invasive upper endoscopy and colonoscopy to directly sample mucosal-associated gut microbiota rather than relying solely on stool. In colonized mice and in human participants, probiotics encountered significant indigenous mucosal colonization resistance; human participants exhibited distinct person-specific mucosal colonization patterns, bifurcating into 'permissive' and 'resistant' phenotypes where baseline microbiome and host features prevented mucosal colonization.

1:09:20supportedmoderateDr. Eran Elinav on Microbiome Insights into Personalized Res

In individuals whose guts resisted probiotic colonization, probiotic consumption caused no measurable changes in gut mucosal responsiveness.

"And by sampling these volunteer participants by invasive colonoscopy and endoscopy at different stages of probiotic exposure, we could find that in individuals that consume probiotics but are not able to colonize these exogenous bugs along their gut, we could see absolutely no impact on the gut responsiveness to these exogenous probiotics." (said at 1:09:20)

A clinical trial evaluating human gastrointestinal mucosal responses via upper endoscopies and colonoscopies during empiric probiotic supplementation demonstrated personalized mucosal colonization resistance. In participants displaying mucosal colonization resistance, the probiotic strains were shed in stool without establishing mucosal residence, resulting in an absence of measurable changes in the mucosal microbiome community structure and host mucosal transcriptome.

1:09:55supportedmoderateDr. Eran Elinav on Microbiome Insights into Personalized Res

In individuals where supplemental probiotics colonized the gut, significant impacts were observed on gut mucosal responsiveness.

"However, in the other half of the individuals, the microbiome was much more welcoming, and when they were eating the probiotics, the probiotics at least temporarily were able to colonize along their guts. And in these individuals, we saw that these exogenous microbes indeed had quite significant impacts on our measurements of human responsiveness, or at least in the gut." (said at 1:09:55)

A clinical trial investigating human mucosal colonization by an 11-strain empiric probiotic mix found that humans display person-specific mucosal colonization patterns (distinguishing permissive colonizers from resistant individuals). In permissive individuals where mucosal colonization occurred, probiotic supplementation exerted significant, individualized impacts on mucosal microbial community structure and host gut transcriptome (mucosal gene expression responsiveness).

1:11:15supportedhighDr. Eran Elinav on Microbiome Insights into Personalized Res

Certain bacteria in the microbiome secrete antimicrobial peptides that function as natural antibiotics to inhibit competing bacterial species.

"Another potential set of interactions are mediated by the secretion of what we call antimicrobial peptides, which are these types of natural antibiotics which some microbes are able to secrete, which inhibit others." (said at 1:11:15)

A well-established mechanism of microbial antagonism in the human microbiome is the secretion of ribosomally synthesized antimicrobial peptides known as bacteriocins. Genomic analyses and in vitro studies confirm that widespread bacterial taxa within the human gut (including Firmicutes, Bacteroidetes, Proteobacteria, and Actinobacteria) produce these natural antimicrobial peptides to target, inhibit, or kill closely related strains and competing pathogenic bacterial species.

1:12:05overstatedmoderateDr. Eran Elinav on Microbiome Insights into Personalized Res

Antibiotic administration clears the indigenous microbiome, permitting supplemental probiotics to colonize the gut in humans and mice.

"was that both in the human and the mouse setting, when you disrupt the indigenous microbiome by the administration of antibiotics, for example, you kind of empty out the neighborhood. And now you give probiotics, now the neighborhood is empty and the probiotics are no longer met by resistance, and now they can colonize the gut." (said at 1:12:05)

The claim overstates the effect in mice and implies a complete clearance ("emptying out") of the native flora. A study in human volunteers and mouse models (PMID 30193113) demonstrated that while antibiotic disruption enhanced mucosal probiotic colonization in humans compared to baseline homeostasis, it only mildly improved probiotic colonization in mice. Furthermore, antibiotics perturb rather than completely erase the native microbiota, and post-antibiotic probiotic administration markedly delayed the natural reconstitution of the indigenous human gut microbiome.

1:12:40supportedmoderateDr. Eran Elinav on Microbiome Insights into Personalized Res

Administering probiotics following antibiotic exposure persistently inhibits the natural recolonization and reconstitution of the indigenous gut microbiome.

"But now these probiotics were very persistently inhibiting the return of the indigenous microbiome after antibiotic exposure was no longer present. In other words, by giving probiotics together with antibiotics, we may be protecting some individuals from the adverse effects associated with antibiotic treatment, but the price that we may pay is the creation of a chronic disturbance in the composition of our gut microbiome, with the probiotics very aggressively refusing to leave the neighborhood and colonizing the once-diverse gut and not letting the microbiome repopulate and recolonize." (said at 1:12:40)

A landmark clinical trial evaluating post-antibiotic gut mucosal microbiome reconstitution in humans and mice demonstrated that multi-strain probiotic administration following broad-spectrum antibiotic perturbation markedly delayed and persistently impaired the recovery and reconstitution of the indigenous mucosal and stool microbiome compared to spontaneous recovery. In contrast, autologous fecal microbiome transplantation led to rapid recovery. The study also identified that soluble factors secreted by probiotic strains (such as Lactobacillus) directly contributed to the inhibition of indigenous gut bacteria.

1:17:48supportedhighDr. Eran Elinav on Microbiome Insights into Personalized Res

Stool sampling does not accurately reflect whether probiotics colonize the gastrointestinal mucosa, as shed bacteria accumulate in stool regardless of colonization.

"And and we are the first to study this colonization pattern not in stool, which which is where most of the previous studies have looked into probiotics. We found that this stool is is very problematic in assessing colonization because even in people who do not colonize at all with probiotics, you know, they end up accumulating in stool because that's the natural way where they go. So you need to really sample inside the gut in order to understand whether a person colonizes or not." (said at 1:17:48)

A clinical trial evaluating human gut mucosal colonization during probiotic consumption demonstrated that probiotic strains were detectable in stool across individuals regardless of whether mucosal colonization actually occurred. Invasive sampling of the human gastrointestinal tract revealed person-, region-, and strain-specific mucosal colonization resistance patterns that could not be predicted or distinguished by examining probiotic presence in stool samples.

1:21:21overstatedhighDr. Eran Elinav on Microbiome Insights into Personalized Res

No probiotic preparation has been approved as a medical drug intervention by the FDA or the European Medicines Agency.

"And and the evidence is that not a single probiotic preparation to date has been approved as a medical intervention by the FDA or by the European counterparts of the FDA." (said at 1:21:21)

The speaker claims that no probiotic preparation has been approved as a medical intervention by the FDA or its European counterparts (such as the EMA). Regulatory bodies like the FDA classify medical live microorganism preparations under the regulatory framework of Live Biotherapeutic Products (LBPs) rather than under the traditional dietary supplement definition of "probiotic." However, the FDA has formally approved live microbial drug interventions to prevent recurrent *Clostridioides difficile* infection, such as Rebyota (fecal microbiota live-jslm) and Vowst (fecal microbiota spores live-brpk). While traditional dietary probiotic products sold over the counter lack FDA/EMA drug approval, the claim that no live bacterial/microbial therapeutic preparation has been approved as a medical drug intervention by the FDA is incorrect.

1:22:21supportedhighDr. Eran Elinav on Microbiome Insights into Personalized Res

Bacteriophages are viruses that specifically infect and attack bacteria and do not infect humans, mammals, or eukaryotic cells.

"So bacteriophages are intriguing viruses that, in contrast to the viruses that we all, you know, suffer from these days, are viruses that do not infect humans and they do not infect any mammals or any eukaryotic cells. These are viruses that only infect bacteria and only attack bacteria." (said at 1:22:21)

Bacteriophages are defined in microbiological consensus and published literature as viruses that specifically infect and replicate within bacteria. They possess precise host specificity targeting bacterial surface receptors and do not naturally infect humans, mammals, or other eukaryotic cells, which forms the fundamental biological basis for bacteriophage therapy safety.

1:22:45supportedhighDr. Eran Elinav on Microbiome Insights into Personalized Res

CRISPR evolved naturally as a bacterial defense mechanism against bacteriophage viruses.

"It's an intriguing arms race which led to some groundbreaking discoveries such as CRISPR, which is the, you know, one of these defense mechanisms which has been now massively exploited by science in order to genome-edit, for example, genes of interest." (said at 1:22:45)

CRISPR-Cas systems evolved in bacteria and archaea as adaptive immune systems that protect prokaryotic cells against invading foreign genetic material, predominantly bacteriophages (viruses) and plasmids. This naturally occurring anti-phage defense mechanism relies on incorporating fragments of viral DNA into the host genome to recognize and cleave matching sequences during subsequent infections, and it has since been adapted widely as a tool for targeted genome editing.

1:28:25overstatedhighDr. Eran Elinav on Microbiome Insights into Personalized Res

Antibiotic interventions increased human lifespan by close to 30 years within a century.

"You know, they increased, I think, close to 30 years of lifespan within a century, and and at least partially took care of what is considered to be our number one, two, and three cause of mortality for millions of years." (said at 1:28:25)

Total U.S. life expectancy increased by 29.2 years during the 20th century, driven largely by reductions in infectious disease mortality (pneumonia, tuberculosis, and diarrhea/enteritis were indeed the top three causes of death in 1900). However, attributing this full 30-year gain specifically to antibiotic interventions overstates their role. Antibiotics were not introduced into clinical use until the 1940s, whereas substantial declines in infectious mortality occurred earlier in the 20th century as a result of broad public health and environmental interventions, including clean water systems, improved sanitation, food safety, hygiene, and vaccination.

1:29:10supportedhighDr. Eran Elinav on Microbiome Insights into Personalized Res

The human body harbors more than 3 million bacterial genes in addition to approximately 20,000 human genes.

"you know, in a matter of a decade and a half, we've discovered that our human body, in addition to the 20-something-thousand genes that are encoded in our human cells, also contain 3 million and more bacterial genes that we didn't appreciate, that we didn't know anything about." (said at 1:29:10)

Metagenomic sequencing of the human microbiome established a reference catalogue of approximately 3.3 million non-redundant microbial genes (over 99% of which are bacterial), representing approximately 150 times the ~20,000–25,000 protein-coding genes encoded in the human genome.

1:34:08supportedhighDr. Eran Elinav on Microbiome Insights into Personalized Res

Dietary compounds including choline and carnitine are converted by gut microbes into TMA, which is then metabolized by the host liver into TMAO.

"we're talking about a connection between dietary compounds such as choline and carnitine, which are digested by the microbes into a compound called TMA, which then influxes into the host and is further converted by the host, by the liver of the host, into TMAO." (said at 1:34:08)

The described meta-organismal metabolic pathway is well-established. Dietary precursors containing quaternary amines, including choline, phosphatidylcholine, and L-carnitine, are cleaved by gut microbial enzymes (such as choline TMA-lyase and carnitine oxygenase) to form trimethylamine (TMA). TMA is absorbed across the intestinal epithelium into portal circulation and transported to the liver, where it is oxidized to trimethylamine N-oxide (TMAO) primarily by host hepatic flavin-containing monooxygenases (predominantly FMO3).

1:34:08supportedmoderateDr. Eran Elinav on Microbiome Insights into Personalized Res

Circulating TMAO can impact macrophages that contribute to atherosclerotic plaque formation.

"And this TMAO swims into the circulation, where in some instances it could impact macrophages that form plaques that are responsible for atherosclerosis and its potentially devastating health effects: heart disease, brain disease, kidney disease, and and more." (said at 1:34:08)

Published preclinical and observational research demonstrates that circulating trimethylamine N-oxide (TMAO) promotes atherosclerosis by directly modulating macrophage biology. In experimental models, TMAO upregulates macrophage scavenger receptors (such as CD36 and SR-A1), increases oxidized LDL uptake, impairs cholesterol efflux, and promotes macrophage foam cell formation and inflammatory cytokine production within vascular plaques.

1:36:11supportedvery lowtheir own paperDr. Eran Elinav on Microbiome Insights into Personalized Res

Interactions between the microbiome and host generate compounds that drive the obesity that develops after smoking cessation.

"we've recently published another study focusing on a peculiar type of obesity that develops after cessation of cigarette smoking. And to make a long story short, we found a similar cooperation between the microbiome and the host in generating compounds that could drive this obesity phenomenon after smoking cessation." (said at 1:36:11)

A 2021 study by the speaker's group published in Nature demonstrated that gut microbiota changes driven by cigarette smoke exposure and cessation promote smoking-cessation-induced weight gain in mouse models. The mechanism involved concerted host and microbiome metabolic cooperation, specifically shunting dietary choline to dimethylglycine (driving increased energy harvest) alongside the depletion of N-acetylglycine. Because the primary causal mechanism was established in animal models with only preliminary observational human cohort data, the certainty of evidence for human clinical outcomes remains very low.

1:38:14supportedmoderateDr. Eran Elinav on Microbiome Insights into Personalized Res

Maintaining healthy sleep patterns and avoiding erratic sleep-wake behavior affects the microbiome and host regulation of weight and glucose metabolism.

"maintaining healthy sleep patterns and avoiding as much as possible erratic sleep-wake behavior has very profound effects on on our measurement of the microbiome and how it impacts our regulation of of weight and and the glucose or sugar metabolism or the avoidance of type 2 diabetes, for example." (said at 1:38:14)

The speaker's claim is supported. Published preclinical and clinical research demonstrates that circadian and sleep disruptions (such as erratic sleep-wake schedules, shift work, and sleep fragmentation) disrupt the diurnal rhythmicity and taxonomic composition of the gut microbiota. Mechanistic studies show that microbiota alterations resulting from circadian desynchrony impair short-chain fatty acid fermentation, disrupt host peripheral clock gene expression, promote weight gain, and induce insulin resistance and glucose intolerance.

1:39:14supportedlowtheir own paperDr. Eran Elinav on Microbiome Insights into Personalized Res

Cigarette-related chemicals reach the systemic circulation, penetrate the gut, and alter the composition and function of the microbiome.

"when we measure what it does to the microbiome, we were intrigued to find that many cigarette-related chemicals not only reach the systemic circulation, but they actually penetrate the gut and they impact the microbiome towards a disturbed composition and function." (said at 1:39:14)

Published experimental research in animal models, supported by preliminary human observational data, confirms that inhaled cigarette smoke-derived chemicals enter the systemic circulation, penetrate the gastrointestinal tract, and drive compositional and functional changes (dysbiosis) in the gut microbiome. A landmark 2021 study showed that an intestinal influx of cigarette-smoke-related metabolites directly alters gut microbial composition and function, modulating host metabolism and energy harvest.

1:40:17supportedmoderateDr. Eran Elinav on Microbiome Insights into Personalized Res

Dietary meal timing, including the timing of dinner the previous night, serves as a predictive feature for postprandial glycemic response algorithms.

"in our personalized nutrition machine learning algorithms, which are used to predict a person's dietary responses in a very accurate manner, the timing of our diet and even the timing of our meal last night are part of the features that are used by this unbiased algorithm in order to form its very accurate predictions." (said at 1:40:17)

Machine-learning models developed for personalized nutrition to predict postprandial glycemic responses incorporate contextual dietary factors, including meal timing, time elapsed since the previous meal, and previous nutritional intake, alongside microbiome, anthropometric, and clinical blood parameters. In a landmark cohort study of 800 individuals tracking continuous glucose across tens of thousands of meals (validated in an independent cohort and a randomized dietary intervention), these multidimensional features accurately predicted individualized postprandial glycemic responses to real-world meals.

1:41:20supportedmoderateDr. Eran Elinav on Microbiome Insights into Personalized Res

In a 2015 study of 1,000 individuals, machine learning algorithms integrating continuous glucose monitoring and microbiome data accurately predicted personalized glycemic responses to food.

"we analyzed the data from a thousand individuals in Israel that kindly gave us a week of their life, and we measured and collected an unprecedented amount of microbiome and host-related data, including a smartphone app that was used in this study and a continuous glucose measurement that generated very accurate measurements of sugar responses to food in a week of follow-up. And then very sophisticated machine learning and AI technologies were used to generate predictive algorithms for each individual that are able to accurately predict a person's sugar responses to any given food." (said at 1:41:20)

In a 2015 landmark study published in Cell by Zeevi et al. (the research group of Eran Segal and Eran Elinav), researchers continuously monitored glucose levels for a week in an 800-person discovery cohort (measuring responses to 46,898 meals) and a 100-person validation cohort in Israel. They developed a machine-learning algorithm incorporating gut microbiota, blood parameters, anthropometrics, and dietary habits to accurately predict personalized postprandial glycemic responses to meals.

1:41:20supportedmoderatetheir own paperDr. Eran Elinav on Microbiome Insights into Personalized Res

A randomized clinical trial demonstrated that a personalized, data-driven diet outperformed the American Diabetes Association-recommended diet in controlling blood glucose in pre-diabetic individuals.

"tested by us in different contexts, including recently in a long-term randomized human trial which compared this data-driven personalized approach to the gold standard American Diabetes Association-recommended diet. And we've quite convincingly showed that this personalized, science-driven approach was outperforming the current one-size-fits-all diet in a large group of pre-diabetic individuals" (said at 1:41:20)

A 2021 randomized controlled trial (Ben-Yacov et al., published in Diabetes Care) evaluated 225 adults with prediabetes assigned to either a personalized postprandial-targeting (PPT) diet driven by machine-learning algorithms or a standard Mediterranean diet (an ADA-recommended dietary pattern). Over a 6-month intervention and subsequent 6-month follow-up, the personalized diet led to significantly greater reductions in daily time spent with glucose >140 mg/dL and greater reductions in HbA1c compared to the Mediterranean diet.

1:48:29needs contextmoderateDr. Eran Elinav on Microbiome Insights into Personalized Res

For some individuals, eating tomatoes alone causes a sharp rise in blood glucose, whereas combining tomatoes with white bread reduces the glycemic response.

"Some people spike their blood sugar to the roof when they eat tomatoes. Now you combine tomatoes with some white bread and the response goes down." (said at 1:48:29)

In a 2015 study of personalized glycemic responses in an 800-person cohort (Zeevi et al., PMID 26590418), researchers continuously monitored postprandial blood glucose levels and observed high interpersonal variability in response to identical foods, including cases where specific participants showed unexpected glycemic spikes to individual foods. However, claims describing extreme paradoxical responses—such as a sharp glycemic spike from tomatoes alone that decreases when combined with white bread—rely on anecdotal highlights or informal presentations of individual participant data from continuous glucose monitoring cohorts rather than established, peer-reviewed findings showing that adding high-glycemic carbohydrates like white bread lowers overall postprandial glucose excursions compared to vegetables alone.

Fact-checked episodes

Publications